New hope for Tough-to-Treat blood cancer: experimental drug added to standard chemo
NCT ID NCT06947967
Summary
This study is testing whether adding an experimental drug called tucidinostat to standard CHOP chemotherapy works better than CHOP alone for adults newly diagnosed with a specific type of T-cell lymphoma. The goal is to better control the cancer and keep it from coming back longer. About 224 participants will be randomly assigned to receive either the real tucidinostat or a placebo pill alongside their chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, T-CELL, PERIPHERAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.